Schiffmann R - Search Results

1

Somatosensory evoked potentials as a marker of disease burden in type 3 Gaucher disease.

Garvey MA, Toro C, Goldstein S, Altarescu G, Wiggs EA, Hallett M, Schiffmann R. Garvey MA, et al. Among authors: schiffmann r. Neurology. 2001 Feb 13;56(3):391-4. doi: 10.1212/wnl.56.3.391. Neurology. 2001. PMID: 11171908

2

The saccadic and neurological deficits in type 3 Gaucher disease.

Benko W, Ries M, Wiggs EA, Brady RO, Schiffmann R, Fitzgibbon EJ. Benko W, et al. Among authors: schiffmann r. PLoS One. 2011;6(7):e22410. doi: 10.1371/journal.pone.0022410. Epub 2011 Jul 20. PLoS One. 2011. PMID: 21799847 Free PMC article. Clinical Trial.

3

Cognitive outcome in treated patients with chronic neuronopathic Gaucher disease.

Goker-Alpan O, Wiggs EA, Eblan MJ, Benko W, Ziegler SG, Sidransky E, Schiffmann R. Goker-Alpan O, et al. Among authors: schiffmann r. J Pediatr. 2008 Jul;153(1):89-94. doi: 10.1016/j.jpeds.2007.12.023. Epub 2008 Feb 14. J Pediatr. 2008. PMID: 18571543

4

Variation in cognitive function over time in Gaucher disease type 3.

Steward AM, Wiggs E, Lindstrom T, Ukwuani S, Ryan E, Tayebi N, Roshan Lal T, Lopez G, Schiffmann R, Sidransky E. Steward AM, et al. Among authors: schiffmann r. Neurology. 2019 Dec 10;93(24):e2272-e2283. doi: 10.1212/WNL.0000000000008618. Epub 2019 Nov 12. Neurology. 2019. PMID: 31719137 Free PMC article.

5

Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease.

Moore DF, Altarescu G, Herscovitch P, Schiffmann R. Moore DF, et al. Among authors: schiffmann r. BMC Neurol. 2002 Jun 18;2:4. doi: 10.1186/1471-2377-2-4. BMC Neurol. 2002. PMID: 12079501 Free PMC article. Clinical Trial.

6

Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.

Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, Barton NW. Altarescu G, et al. Among authors: schiffmann r. Blood Cells Mol Dis. 2000 Aug;26(4):285-90. doi: 10.1006/bcmd.2000.0310. Blood Cells Mol Dis. 2000. PMID: 11042029 Clinical Trial.

7

The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease.

Altarescu G, Hill S, Wiggs E, Jeffries N, Kreps C, Parker CC, Brady RO, Barton NW, Schiffmann R. Altarescu G, et al. Among authors: schiffmann r. J Pediatr. 2001 Apr;138(4):539-47. doi: 10.1067/mpd.2001.112171. J Pediatr. 2001. PMID: 11295718

8

The neurogenetics of mucolipidosis type IV.

Altarescu G, Sun M, Moore DF, Smith JA, Wiggs EA, Solomon BI, Patronas NJ, Frei KP, Gupta S, Kaneski CR, Quarrell OW, Slaugenhaupt SA, Goldin E, Schiffmann R. Altarescu G, et al. Among authors: schiffmann r. Neurology. 2002 Aug 13;59(3):306-13. doi: 10.1212/wnl.59.3.306. Neurology. 2002. PMID: 12182165

9

Mucolipidosis type IV: characteristic MRI findings.

Frei KP, Patronas NJ, Crutchfield KE, Altarescu G, Schiffmann R. Frei KP, et al. Among authors: schiffmann r. Neurology. 1998 Aug;51(2):565-9. doi: 10.1212/wnl.51.2.565. Neurology. 1998. PMID: 9710036

10

Profile of endothelial and leukocyte activation in Fabry patients.

DeGraba T, Azhar S, Dignat-George F, Brown E, Boutière B, Altarescu G, McCarron R, Schiffmann R. DeGraba T, et al. Among authors: schiffmann r. Ann Neurol. 2000 Feb;47(2):229-33. Ann Neurol. 2000. PMID: 10665494

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

323 results

Search Page

Filters